T-cell immunoglobulin mucin-3 expression levels in pediatric acute myeloid leukemia
The Egyptian journal of Immunology · 2025
DOI: 10.55133/eji.320306 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Egyptian journal of Immunology, 2025. Verfasst von Mona Sultan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Biochemistry, Department of Chemistry, Faculty of Science, Cairo University, Giza, Egypt. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Hepatitis A Virus Cellular Receptor 2, Biomarkers, Tumor, Neoplastic Stem Cells.
Abstract (Originalsprache)
Acute myeloid leukemia (AML) is a hematological ailment characterized via specific clinical and molecular heterogeneous disorders. It is associated with poor long-term survival, even with new chemotherapy regimens. T-cell immunoglobulin and mucin domain-3 (TIM-3) is a membrane protein expressed in various kinds of immune cells. Recent studies reported that higher TIM-3 expression levels correlate with advanced tumor stages and poor prognosis in several solid tumors. This study aimed to evaluate the expression of TIM-3 as a specific marker of leukemia stem cells (LSCs) in pediatric patients with newly diagnosed AML, and its possible role as a prognostic biomarker. The expression levels of TIM-3 were assessed in the bone marrow aspirate (BMA) of 32 newly diagnosed pediatric AML cases and 10 control subjects by flow cytometry on (CD34+/CD38+) fraction, as well as on (CD34+/CD38-) fraction, at the time of diagnosis and at the end of the first cycle of chemotherapy (first induction). These expression levels in patients were then correlated with clinical outcome. TIM-3 expression levels were significantly higher in pediatric AML patients on LSCs (CD34+/CD38-) and leukemic progenitors (CD34+/CD38+) fractions compared to the control group (p-value < 0.001). TIM-3 expression levels on LSCs (CD34+/CD38-) fraction were associated with a higher mortality risk and short survival. In conclusion, T-cell immunoglobulin and mucin domain-3 (TIM-3) may serve as LSCs specific biomarker for poor prognosis in pediatric AML patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Biochemistry, Department of Chemistry, Faculty of Science, Cairo University, Giza, Egypt.
- Department of Clinical Pathology, National Cancer Institute, Cairo University, Giza, Egypt.
- Department of Clinical Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
- Department Pediatric Oncology, National Cancer Institute Cairo University, Giza, Egypt.
Zitieren
APA
Sultan, M., Ibrahim, M. S. M., Abdur-Rahman, M., Dessouki, O. F. A., Ebeid, E. N., & Eldesouky, M. A. (2025). T-cell immunoglobulin mucin-3 expression levels in pediatric acute myeloid leukemia. The Egyptian journal of Immunology. https://doi.org/10.55133/eji.320306
Vancouver
Sultan M, Ibrahim MSM, Abdur-Rahman M, Dessouki OFA, Ebeid EN, Eldesouky MA. T-cell immunoglobulin mucin-3 expression levels in pediatric acute myeloid leukemia. The Egyptian journal of Immunology. 2025. doi:10.55133/eji.320306
BibTeX
@article{Sultan2025,
author = {Sultan, Mona and Ibrahim, Maha S M and Abdur-Rahman, Mariam and Dessouki, Omar F A and Ebeid, Emad N and Eldesouky, Mohamed A},
title = {T-cell immunoglobulin mucin-3 expression levels in pediatric acute myeloid leukemia},
journal = {The Egyptian journal of Immunology},
year = {2025},
doi = {10.55133/eji.320306}
}
EUVIMED